ASTRAZENECA PLC

AZN

Held by 3 specialist biotech funds

High Convergence

3 funds opened new positions. Next phase3 readout (Anastozole (Arimidex)): Jun 2001. Short interest: 0.1% of float.

Drug Manufacturers - GeneralCEO: Pascal Claude Roland SoriotIPO: 1993Website ↗

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Catalysts

Phase 3PositiveQ2 2001Anastozole (Arimidex)Breast CancerNCT00849030

Primary: Time to recurrence of breast cancer (Earliest of local or distant recurrence, new primary breast cancer, or death)Enrollment:9,358/9,358RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ3 2002EsomeprazoleNSAIDs, Upper GI SymptomsNCT00241527

Primary: Mean change in the upper GI symptoms (pain, discomfort orEnrollment:Target 556Sites: 130RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2003budesonide/formoterolAsthmaNCT00651547

Primary: Morning PEF (Daily)Enrollment:Target 405RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ1 2004RosuvastatinHypercholesterolemiaNCT00379249

Primary: Cumulative direct/indirect disease-related costs were compared applying a societal perspectiveEnrollment:Target 8,000RANDOMIZED, TREATMENT

Phase 2Q2 2004SaxagliptinType 2 Diabetes MellitusNCT00950599

Primary: Analysis of Test for Positive Efficacy Trend in Change From Baseline in Hemoglobin A1c (A1C) at Week 12 in the 0-40 mg Cohort (Baseline, Week 12)Enrollment:423/423RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2004budesonideAsthmaNCT00642161

Primary: Change from Baseline in % predicted Forced Expiratory Volume in 1 second (Week 2, 4 and 8, then at week 12)Enrollment:Target 430RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2004CiclesonideRhinitis, Allergic, Seasonal, Hay FeverNCT00659841

Primary: Average of AM and PM patient-reported reflective Total Nasal Symptom Score (TNSS) over the first two weeks of treatment (4 weeks)Enrollment:302/302Sites: 6RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2005budesonide/formoterol, 2x 200/6 microgram. 4 times dailyChronic Obstructive Pulmonary DiseaseNCT00239278

Primary: Eosinophils in induced sputum (as % of Total Cell Count), change from the start of the exacerbation to the end of 14 days treatmentEnrollment:Target 120Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2005RosuvastatinHypercholesterolaemiaNCT00654303

Primary: Safety, as determined by adverse events, laboratory data, physical examination and ECG. (12 weekly)Enrollment:Target 3,500NON_RANDOMIZED, TREATMENT

Phase 3Q3 2005QuetiapinePsychotic DisordersNCT00254813

Primary: Proportion of patients with moderate and severe adverse eventsEnrollment:Target 150Sites: 7RANDOMIZED, TREATMENT

Phase 3Q4 2005CiclesonideAsthmaNCT00163462

Primary: FEV1 absolute valuesEnrollment:Target 750Sites: 57RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2005AnastrazoleBreast CancerNCT00255463

Primary: To determine and compare changes in proliferation marker at 16 weeks in the treatment groupsEnrollment:Target 185Sites: 34RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2006Budesonide/formoterol TurbuhalerAsthmaNCT00259792

Primary: Time to first severe asthma exacerbationEnrollment:Target 1,000Sites: 82RANDOMIZED, TREATMENT

Phase 2NegativeQ1 2006NXY-059Intracerebral HemorrhageNCT00075959

Primary: Global disability on modified Rankin scale at 90 daysEnrollment:Target 600Sites: 64RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ2 2006GefitinibMetastatic Breast CancerNCT00319618

Primary: Objective tumour response (CR + PR) per RECIST criteriaEnrollment:Target 66Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2006RoflumilastBronchial AsthmaNCT00242307

Primary: change in lung function parameters.Enrollment:450/450Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ3 2006NXY-059Cerebral Stroke, Stroke, Acute, Cerebrovascular StrokeNCT00061022

Primary: Global disability on modified Rankin scale at 90 days.Enrollment:Target 3,200Sites: 256RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2006quetiapine fumarateBipolar I DisorderNCT00107731

Primary: Evaluate the efficacy of quetiapine versus placebo when used as adjunct therapy to mood stabilizer in increasing time to recurrence of a mood event.Enrollment:Target 710Sites: 166RANDOMIZED, DOUBLE, PREVENTION

Phase 3NegativeQ4 2006TesaglitazarType 2 DiabetesNCT00255541

Primary: Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)Enrollment:Target 580Sites: 66RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2007quetiapine fumarate tabletsSchizophreniaNCT00090324

Primary: Compare efficacy of Quetiapine with placebo in the treatment of schizophrenia as assessed by the PANSS total score, change from baseline to Day 42Enrollment:Target 249Sites: 42RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 2007SaxagliptinDiabetesNCT00316082

Primary: Change From Baseline in Hemoglobin A1 (A1C) at Week 24 (Baseline, Week 24)Enrollment:365/365Sites: 74RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2008ABT-335 and rosuvastatin calciumHypercholesterolemia, DyslipidemiaNCT00463606

Primary: Mean Percent Change From Baseline to the Final Visit in High-density Lipoprotein Cholesterol (HDL-C) (Full Analysis Set) (Baseline to 12 Weeks)Enrollment:760/760Sites: 168RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2008Symbicort TurbuhalerBronchial AsthmaNCT00536731

Primary: Morning Peak Expiratory Flow (PEF) (Baseline to 6 weeks)Enrollment:742/742Sites: 48RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2008exenatideDiabetes Mellitus, Type 2NCT00135330

Primary: Change in ASIiAUC During a Hyperglycemic Clamp Test. (20 weeks)Enrollment:137/137Sites: 19RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2008AZD3480Alzheimer DiseaseNCT00501111

Primary: Change in ADAS-Cog (assessed after 12 weeks treatment)Enrollment:659/659Sites: 70RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2008BicalutamideNon-Metastatic Prostate CancerNCT00672282

Primary: Survival (Throughout study period)Enrollment:1,218/1,218Sites: 54RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2009FulvestrantBreast CancerNCT00099437

Primary: Time to Progression (TTP) (RECIST(Response Evaluation Criteria in Solid Tumors ) tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months))Enrollment:736/736Sites: 106RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ2 2009AZD9668BronchiectasisNCT00769119

Primary: Ratio of Absolute Neutrophil Count at End of Treatment Compared to Baseline (End of treatment values from 3 visits (day 21 to 28) and baseline values from 3 visits.)Enrollment:38/38Sites: 9RANDOMIZED, QUADRUPLE, BASIC_SCIENCE

Phase 2PositiveQ2 2009RosuvastatinHyperlipidemiaNCT00296400

Primary: Urinary Protein/Creatinine Ratio at Week 52 [LOCF] (Assessed at baseline and Week 52 (LOCF))Enrollment:237/237Sites: 107RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2009exenatide once weeklyType 2 Diabetes MellitusNCT00894322

Primary: Area Under the Curve (AUC) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population (Day 1, Week 12)Enrollment:65/65Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 3Q3 2009BudesonideAsthmaNCT00855959

Primary: Morning Peak Expiratory Flow (mPEF) (6 weeks)Enrollment:108/108Sites: 6NON_RANDOMIZED, TREATMENT

Phase 2Q4 2009AZD2171Metastatic Colorectal CancerNCT00494221

Primary: Progression Free Survival (RECIST at Baseline, Weeks 6, 12, 18, 24 and then every 12 weeks until progression through to a cut-off date of 13th Oct 2009 (based on approx 105 progression events observed across the 3 groups))Enrollment:172/172Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2009FulvestrantPuberty, Precocious, Mc Cune-Albright SyndromeNCT00278915

Primary: Change in Frequency of Annualized Days of Vaginal Bleeding on Treatment Compared to Baseline (Baseline (6 month pre-treatment observation period) through Month 12 treatment period)Enrollment:30/30Sites: 16NA, TREATMENT

Phase 3PositiveQ1 2010DapagliflozinType 2 DiabetesNCT00683878

Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) (From Baseline to Week 24)Enrollment:972/972Sites: 89RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ1 2011AZD2423Chronic Obstructive Pulmonary Disease, Lung DiseaseNCT01215279

Primary: Number of Participants With Clinically Significant Changes in Laboratory Variables Other Than Monocytes (Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up))Enrollment:63/63Sites: 6RANDOMIZED, TRIPLE, BASIC_SCIENCE

Phase 2PositiveQ4 2011olaparibOvarian CancerNCT01081951

Primary: Progression Free Survival (PFS) (Radiologic scans performed at weeks 9 and 18 (+/-1 week) and every 12 weeks thereafter relative to the date of randomisation until the primary analysis (approximately 20 months))Enrollment:162/162Sites: 53RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2011AZD6765Treatment Resistant Major Depressive DisorderNCT00986479

Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. (60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.)Enrollment:22/22Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ1 2012TC-5214Major Depressive DisorderNCT01197508

Primary: Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment. (Randomization (Week 8) to end of treatment (Week 16))Enrollment:696/696Sites: 87RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2012Aclidinium/formoterol 400/12μgChronic Obstructive Pulmonary Disease (COPD)NCT01551888

Primary: Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval at Steady State (Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose; Days 2-4: 0, 5 and 15 min post dose; Day 5: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (post AM dose))Enrollment:24/24Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2012AZD8931Neoplasms, Breast Neoplasms, Breast CancerNCT00900627

Primary: Phase I: The Number of Dose Limiting Toxicities in AZD8931 in Combination With Weekly Paclitaxel (Weekly visits for routine safety monitoring from Day 1 to Day 28 for each participant)Enrollment:330/330Sites: 38RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2012Olive oil, 4gHypertriglyceridemia, Cardiovascular DiseaseNCT01408303

Primary: Serum Non-HDL Cholesterol (6 weeks)Enrollment:646/646Sites: 89RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2013DapagliflozinType 2 DiabetesNCT01137474

Primary: Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12 (From Baseline to Week 12)Enrollment:2,996/2,996Sites: 329RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ1 2013fostamatinibRheumatoid ArthritisNCT01197534

Primary: Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo (24 weeks)Enrollment:913/913Sites: 149RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2014CiclesonideSeasonal Allergic RhinitisNCT02155881

Primary: Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Reflective Total Nasal Symptom Scores (TNSS) (Baseline and Week 1 up to Week 2 (entire treatment period))Enrollment:80/80Sites: 5RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2016BenralizumabAsthmaNCT02417961

Primary: Number and Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home (Week 12, Week 16, and Weeks 12 and 16)Enrollment:162/162Sites: 23NA, TREATMENT

Phase 3Q2 2016SelumetinibLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVNCT01933932

Primary: Progression-Free Survival (PFS) (Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI))Enrollment:510/510Sites: 197RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2016Olaparib 300mg tabletsPlatinum Sensitive, BRCA Mutated, Relapsed Ovarian CancerNCT01874353

Primary: Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1) (Radiologic scans performed at baseline then every ~12 weeks up to 72 weeks, then every ~ 24 weeks thereafter until objective radiological disease progression. Assessed until 19 Sep 2016 DCO (16 Jan 2017 DCO for China Cohort); up to a maximum of 36 months.)Enrollment:327/327Sites: 126RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2016SaxagliptinType 2 DiabetesNCT02284893

Primary: Mean Change in HbA1c (Baseline (randomization) to Week 26)Enrollment:461/461Sites: 79RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2017TralokinumabAsthmaNCT02449473

Phase 3NegativeQ1 2018Tralokinumab open-labelInadequately Controlled AsthmaNCT02902809

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Screening (Day -14) up to 14 weeks after end of treatment (Week 66).)Enrollment:28/28Sites: 3NA, TREATMENT

Phase 3Q2 2018Olaparib 300mg tabletsNewly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IVNCT01844986

Primary: Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1) (Radiologic scans performed at baseline then every 12 weeks up to 156 weeks, then every 24 weeks thereafter until objective radiological disease progression. DCO: 17 May 2018)Enrollment:450/450Sites: 177RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2018MEDI4736Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHNNCT02369874

Phase 3Q4 2018MEDI4736 (Durvalumab)Non-Small-Cell Lung Carcinoma NSCLCNCT02453282

Primary: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).)Enrollment:1,118/1,118Sites: 196RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2019olaparibMetastatic Castration-resistant Prostate CancerNCT02987543

Primary: Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only (Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).)Enrollment:387/387Sites: 204RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2019SavolitinibCarcinoma, Carcinoma, Renal Cell, Kidney NeoplasmsNCT03091192

Primary: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (RECIST tumour assessments every 6 weeks from randomisation until disease progression as defined by Recist 1.1 and confirmed by BICR.)Enrollment:60/60Sites: 59RANDOMIZED, TREATMENT

Phase 2MixedQ4 2019AZD9567Rheumatoid ArthritisNCT03368235

Primary: Least Square (LS) Mean Change From Baseline in 28 Joint Disease Activity Score Using C-Reactive Protein (DAS28-CRP) at Day 15 (Baseline (Day 1) and Day 15)Enrollment:21/21Sites: 5RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2020MEDI4736 (Durvalumab)Urothelial CancerNCT02516241

Primary: To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set (From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).)Enrollment:1,126/1,126Sites: 222RANDOMIZED, TREATMENT

Phase 3PositiveQ1 2020DurvalumabSmall Cell Lung Carcinoma Extensive DiseaseNCT03043872

Primary: Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP (From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months).)Enrollment:987/987Sites: 207RANDOMIZED, TREATMENT

Phase 3Q1 2020OlaparibBreast CancerNCT02032823

Primary: Invasive Disease Free Survival (IDFS) (From date of randomisation to data cut off: 27 March 2020 (approximately 5 years 11 months))Enrollment:1,837/1,837Sites: 698RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2020Durvalumab +TremelimumabNon Small Cell Lung Carcinoma NSCLCNCT02542293

Primary: Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).)Enrollment:953/953Sites: 210RANDOMIZED, TREATMENT

Phase 2Q4 2020DurvalumabUrinary Bladder NeoplasmsNCT03459846

Primary: Progression-free Survival (PFS) (Assessments performed at baseline and every 8 weeks from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), assessed up to the data cut-off date (15 Oct 2020), up to a max. of 31 months)Enrollment:154/154Sites: 44RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2020Olaparib Continuous (28-Day cycle) 300 mg BD.Metastatic Triple Negative Breast CancerNCT03330847

Primary: Progression-free Survival Per Stratum (BICR) (Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months))Enrollment:273/273Sites: 141RANDOMIZED, TREATMENT

Phase 3Q4 2020Chronic Obstructive Pulmonary Disease (COPD)NCT04078126

Primary: Peak Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Within 4 Hours Post-dose Following 1 Week of Treatment (baseline and 4 hours post dose after 1 week of treatment)Enrollment:35/35Sites: 4RANDOMIZED, TREATMENT

Phase 2Q1 2021DurvalumabNon-small Cell Lung Cancer NSCLCNCT03775486

Primary: Progression-free Survival (From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months)Enrollment:401/401Sites: 68RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2021DurvalumabNon Small Cell Lung Cancer NSCLCNCT03164616

Primary: Progression-Free Survival (PFS); D + SoC Compared With SoC Alone (Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).)Enrollment:1,186/1,186Sites: 175RANDOMIZED, TREATMENT

Phase 3Q3 2021olaparibMetastatic Castration-resistant Prostate CancerNCT03732820

Primary: Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment (Assessed from date of randomisation to data cut off (DCO1): 30Jul2021 (Approx. 2 years 9 months))Enrollment:895/895Sites: 132RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2021DurvalumabBiliary Tract NeoplasmsNCT03875235

Primary: Overall Survival (OS) (From date of randomization until death due to any cause. Assessed up to maximum of approximately 27 months (from date of randomization to primary analysis data cut-off))Enrollment:810/810Sites: 126RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2021DurvalumabHepatocellular CarcinomaNCT03298451

Primary: Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg (From the date of randomization until death due to any cause, assessed up to the data cut-off date (27Aug2021, to a maximum of approximately 46 months).)Enrollment:1,324/1,324Sites: 160RANDOMIZED, TREATMENT

Phase 2Q3 2021OlaparibOvarian, Breast, SCLCNCT02734004

Primary: Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12 (RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019.)Enrollment:264/264Sites: 47NON_RANDOMIZED, TREATMENT

Phase 2Q4 2021AZD4635Progressive Metastatic Castrate-Resistant Prostate CancerNCT04495179

Primary: Radiographic Progression Free Survival (rPFS) in Each Arm Separately to Determine the Efficacy of AZD4635 Plus Durvalumab and of AZD4635 Plus Durvalumab Plus Cabazitaxel in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) (From first dose to first documented progression or death from any cause (whichever comes first) (approximately 1 year))Enrollment:30/30Sites: 16NON_RANDOMIZED, TREATMENT

Phase 2Q4 2021VerinuradChronic Kidney DiseaseNCT03990363

Primary: Urinary Albumin to Creatinine Ratio (uACR) (mg/g) Change From Baseline at 6 Months (Visit 8), Repeated Measures Mixed Model (MMRM) (Baseline to 9 months (Visit 9); analysis at 6 months (Visit 8))Enrollment:861/861Sites: 165RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2022AZD9291 80 mg/40 mgStage IB-IIIA Non-small Cell Lung CarcinomaNCT02511106

Primary: Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS). (Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months))Enrollment:682/682Sites: 238RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2022MonalizumabSquamous Cell Carcinoma of the Head and NeckNCT04590963

Primary: Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set (Baseline (-28 to -1) through 17.5 months (maximum observed duration))Enrollment:370/370Sites: 127RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2022DurvalumabSmall-Cell Lung CancerNCT04745689

Primary: Maintenance Participants Alive and Progression Free (APF12) Per RECIST 1.1 [Efficacy] (Up to 12 months)Enrollment:31/31Sites: 12NON_RANDOMIZED, TREATMENT

Phase 2Q3 2022600 mg AZD7442 IVCoronavirus Disease 2019 (COVID-19)NCT05184062

Phase 2Q3 2022AZD9833Advanced ER-Positive HER2-Negative Breast CancerNCT04214288

Primary: Progression-free Survival (PFS) (From date of randomisation to date of objective disease progression (or last evaluable assessment in the absence of progression) or death (up to data cut-off of 29 months))Enrollment:240/240Sites: 86RANDOMIZED, TREATMENT

Phase 3Q4 2022Durvalumab (MEDI4736)Non Small Cell Lung Carcinoma NSCLCNCT03003962

Primary: Overall Survival (OS) (From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months [data cut-off (DCO) 27 October 2022])Enrollment:669/669Sites: 92RANDOMIZED, TREATMENT

Phase 3Q4 2022DurvalumabNon-Small Cell Lung CancerNCT03800134

Primary: Pathological Complete Response (pCR) in modified intent-to-treat (mITT) population (Up to approximately 15 weeks after randomization)Enrollment:825/825Sites: 231RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2022Osimertinib + SavolitinibNon-Small Cell Lung CancerNCT04606771

Primary: Objective Response Rate (ORR) (Tumour assessments every 6 weeks from randomisation up to 24 weeks, then every 8 weeks until objective disease progression (maximum of approximately 25 months))Enrollment:30/30Sites: 21RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2022AcalabrutinibPhase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT03932331

Primary: Phase I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From the first dose administration up to 30 days following the date of last dose of study treatment, approximately 25 months.)Enrollment:105/105Sites: 23NON_RANDOMIZED, TREATMENT

Phase 2Q1 2023Trastuzumab deruxtecanAdvanced Solid Tumors With HER2 Mutation, eg:Colorectal, Urothelial, Gastric, Hepatobiliary, Endometrial, Melanoma, Ovarian, Cervical, Salivary Gland, Pancreatic, BreastNCT04639219

Primary: Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR) (Tumor scans performed at screening,then every 6 weeks (q6w) +/- 1 week relative to date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months))Enrollment:102/102Sites: 30NA, TREATMENT

Phase 2Q1 2023Durvalumab / Tremelimumab Combination TherapyPediatric Cancer, Solid Tumor Pediatric, Hematological MalignanciesNCT03837899

Primary: Dose-Finding Phase: Maximum Serum Concentration (Cmax) of Durvalumab (Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12)Enrollment:50/50Sites: 19NON_RANDOMIZED, TREATMENT

Phase 3Q2 2023OsimertinibNon-Small Cell Lung CancerNCT04035486

Primary: Adverse Events Graded by Common Terminology Criteria for Adverse Event v5 (Safety Run-In Treatment Arms Only) (From first dose date to 28 days following last dose, up to 45 months)Enrollment:587/587Sites: 153RANDOMIZED, TREATMENT

Phase 3Q2 2023FulvestrantLocally Advanced (Inoperable) or Metastatic Breast CancerNCT04305496

Primary: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.)Enrollment:818/818Sites: 215RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2023BenralizumabEosinophilic Granulomatous VasculitisNCT04157348

Primary: Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48 (Week 36 and Week 48)Enrollment:140/140Sites: 50RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2023DurvalumabNon-Small Cell Lung CancerNCT03519971

Primary: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).)Enrollment:328/328Sites: 86RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2023DurvalumabHepatocellular CarcinomaNCT03778957

Primary: Progression Free Survival (PFS) for Arm B vs Arm C (Approximately 5 years)Enrollment:724/724Sites: 166RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2023Trastuzumab deruxtecanHER2-mutant Non-Small Cell Lung CancerNCT05246514

Primary: ICR-assessed ORR (Objective Response Rate) (Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months. (from date of enrolment to final analysis data cut-off))Enrollment:72/72Sites: 28NA, TREATMENT

Phase 2Q4 2023Datopotamab Deruxtecan (Dato-DXd)Carcinoma, Non-Small-Cell Lung, Triple Negative Breast CancerNCT05460273

Primary: Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR) (TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.)Enrollment:119/119Sites: 21NA, TREATMENT

Phase 2Q4 2023TezepelumabChronic Obstructive Pulmonary Disease (COPD)NCT04039113

Phase 3Q1 2024AcalabrutinibUntreated Chronic Lymphocytic LeukemiaNCT04075292

Primary: Progression Free Survival (PFS) Assessed by BICR (Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD or death, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months))Enrollment:155/155Sites: 46RANDOMIZED, TREATMENT

Phase 3Q1 2024Osimertinib 80mg/40mgNon Small Cell Lung Cancer (Stage III)NCT03521154

Primary: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) (Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months)Enrollment:216/216Sites: 118RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2024DurvalumabSmall Cell Lung CancerNCT03703297

Primary: Durvalumab Versus Placebo: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (Response evaluations performed every 8 weeks (q8w) ± 1 week up to 72 weeks, then every 12 weeks (q12w) ± 1 week up to 96 weeks, and then every 24 weeks (q24w) thereafter until PD, up to DCO date 15 January 2024 (a maximum of approximately 1936 days))Enrollment:730/730Sites: 183RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2024olaparibMetastatic Castration-resistant Prostate CancerNCT05171816

Primary: Radiological Progression Free Survival (rPFS) (Tumour imaging CT/MRI and bone scan were assessed every 8 weeks from randomisation to week 24 and then every 12 weeks until RECIST progression. Patients were followed up for 479 days (approx 16 months) at minimum and 913 days (approx 30 months) at maximum)Enrollment:110/110Sites: 26RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2024Trastuzumab DeruxtecanBreast CancerNCT04739761

Phase 3Q1 2024Trastuzumab deruxtecanAdvanced or Metastatic Breast CancerNCT04494425

Phase 2Q2 2024CeralasertibMelanomaNCT05061134

Phase 3Q2 2024DurvalumabMuscle Invasive Bladder CancerNCT03732677

Phase 3Q2 2024DurvalumabCarcinoma, Non-Small-Cell LungNCT03706690

Phase 3Q3 2024olaparibEndometrial NeoplasmsNCT04269200

Phase 3Q3 2024Dato-DXdBreast CancerNCT05104866

Phase 2Q3 2024CeralasertibAdvanced or Metastatic NSCLCNCT05941897

Phase 3Q3 2024SelumetinibNeurofibromatosis 1, Plexiform Neurofibroma (PN)NCT04924608

Phase 2Q3 2024osimertinibCarcinomaNCT03778229

Phase 3PositiveQ3 2024NirsevimabRespiratory Syncytial Virus InfectionsNCT06042049

Phase 2Q3 2024DurvalumabNon-Small Cell Lung CancerNCT03334617

Phase 2Q4 2024AZD0171Locally Advanced or Metastatic Solid TumoursNCT04999969

Phase 3Q4 2024CapivasertibHormone-Sensitive Prostate CancerNCT04493853

Phase 3Q4 2024OsimertinibNon-Small Cell Lung CancerNCT04351555

Phase 3Q4 2024Osimertinib (AZD9291) pemetrexed cisplatin or carboplatinNon-small Cell Lung CancerNCT04765059

Phase 2Q4 2024Neoadjuvant Olaparib monotherapy groupBreast CancerNCT05498155

Phase 2Q4 2024DurvalumabTriple Negative Breast NeoplasmsNCT03742102

Phase 2Q4 2024AZD7789Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction CancerNCT04931654

Phase 3Q4 2024DurvalumabGastrointestinal Neoplasms, Esophagogastric JunctionNCT04592913

Phase 2Q1 2025Trastuzumab deruxtecanMetastatic Breast CancerNCT04538742

Phase 2Q1 2025Administration of ceralasertibAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerNCT02264678

Phase 3Q1 2025Trastuzumab DeruxtecanBreast Neoplasms, Breast Cancer, HER2-positive Early Breast CancerNCT05113251

Phase 3Q1 2025BevacizumabAdvanced Ovarian CancerNCT03737643

Phase 3Q1 2025DurvalumabHepatocellular CarcinomaNCT05557838

Phase 3Q2 2025Durvalumab (MEDI4736)Non-muscle-invasive Bladder CancerNCT03528694

Phase 2Q2 2025OsimertinibNon-Small Cell Lung CancerNCT03944772

Phase 3PositiveQ2 2025BenralizumabHypereosinophilic SyndromeNCT04191304

Phase 3Q2 2025DurvalumabNon-Muscle- Invasive Bladder CancerNCT05943106

Primary: Incidence of Grade 3 or 4 Possibly related adverse events (PRAEs) (From the date of the first dose of study treatment (Day 1) until 6 months after the initiation of study treatment)Enrollment:100/100Sites: 19NA, TREATMENT

Phase 3Q2 2025savolitinibPapillary Renal Cell CarcinomaNCT05043090

Phase 3Q2 2025AZD9833ER-Positive HER2-Negative Breast CancerNCT04964934

Phase 3Q3 2025Medi-546Systemic Lupus ErythematosusNCT04877691

Phase 3Q3 2025Dato-DXdBreast CancerNCT05374512

Phase 3Q4 2025DurvalumabBiliary Tract CancerNCT05771480

Phase 3Q4 2025CeralasertibAdvanced or Metastatic Non-Small Cell Lung CancerNCT05450692

Phase 2Q4 2025Trastuzumab deruxtecanAdvanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)NCT06271837

Phase 2Q4 2025AZD9829Hematological MalignanciesNCT06179511

Phase 3Q4 2025BenralizumabSevere Eosinophilic AsthmaNCT06465485

Phase 3PositiveQ4 2025BaxdrostatUncontrolled Hypertension, Resistant HypertensionNCT06344104

Phase 2Q1 2026AtuliflaponAsthmaNCT05251259

Phase 2Q1 2026DurvalumabNon-small Cell Lung CancerNCT05925530

Phase 3PositiveQ1 2026TozorakimabChronic Obstructive Pulmonary Disease (COPD)NCT05158387

Phase 3PositiveQ1 2026TozorakimabChronic Obstructive Pulmonary Disease (COPD)NCT05166889

Phase 2Q1 2026AZD4117Influenza ANCT07128615

Phase 3Q1 2026TremelimumabHepatocellular CarcinomaNCT05301842

Phase 2Q1 2026AZD3470Advanced Solid Tumors That Are MTAP DeficientNCT06130553

Phase 3PositiveQ1 2026Chronic Obstructive Pulmonary Disease (COPD)NCT05742802

Phase 3Q1 2026BDA MDI HFO 160/180 μgAsthmaNCT06502366

Phase 3Q1 2026capivasertibProstate CancerNCT05348577

Phase 3Q1 2026PlaceboChronic Obstructive Pulmonary Disease (COPD)NCT06040086

Phase 3Q1 2026CapivasertibTriple Negative Breast NeoplasmsNCT03997123

Phase 3Q1 2026DurvalumabAdvanced Hepatocellular CarcinomaNCT05883644

Phase 3Q2 2026DurvalumabUnresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial CancerNCT03682068

Phase 3Q2 2026Trastuzumab DeruxtecanLocally Advanced or Metastatic Non-Small Cell Lung CancerNCT05048797

Phase 2Q2 2026PlaceboChronic Obstructive Pulmonary Disease (COPD)NCT06897748

Phase 3Q2 2026DurvalumabMuscle Invasive Bladder CancerNCT04960709

Phase 2Q2 2026AZD7798Moderate to Severe Crohn's DiseaseNCT06450197

Phase 2Q2 2026AZD3470Lymphoma, Non-Hodgkin, Hodgkin LymphomaNCT06137144

Phase 3Q2 2026AZD0901Gastric Cancer, Gastroesophageal Junction CancerNCT06346392

Phase 3Q2 2026EplontersenTransthyretin Amyloid CardiomyopathyNCT06194825

Phase 2Q2 2026AZD9550Obesity or OverweightNCT06862791

Phase 2Q2 2026AZD6234Endocrinology, Diabetes, Type II, ObesityNCT06851858

Phase 3Q2 2026DurvalumabHepatocellular CarcinomaNCT03847428

Phase 3Q2 2026DurvalumabEsophageal Squamous Cell CarcinomaNCT04550260

Primary: Progression free survival (PFS) per RECIST 1.1 as assessed by BICR (up to approximately 56 months)Enrollment:640/640Sites: 133RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2026SavolitinibCarcinoma, Non-Small-Cell LungNCT05261399

Phase 3Q2 2026TozorakimabViral Lung Infection and Acute Respiratory FailureNCT05624450

Phase 2Q2 2026OleclumabNon-Small Cell Lung CancerNCT06606847

Phase 3Q2 2026DurvalumabNon-Small Cell Lung CancerNCT05221840

Phase 2Q3 2026DurvalumabHepatocellular Carcinoma (HCC)NCT06040099

Phase 3Q3 2026Trastuzumab deruxtecanBreast Cancer; HER2-positive; MetastaticNCT04784715

Phase 2Q3 2026OsimertinibLung CancerNCT06194448

Phase 3Q3 2026TezepelumabEosinophilic EsophagitisNCT05583227

Phase 3Q3 2026OlaparibOvarian CancerNCT04884360

Phase 2Q3 2026Zibotentan/DapagliflozinChronic Kidney Disease With High ProteinuriaNCT06942910

Phase 2Q3 2026AZD6234Obesity/OverweightNCT07017179

Phase 2Q3 2026AZD0901Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract CancerNCT06219941

Phase 3Q3 2026Nexium 20mgErosive EsophagitisNCT05267613

Phase 2Q3 2026AZD7798Crohn's DiseaseNCT06681324

Phase 3Q3 2026AZD9833ER-Positive HER2-Negative Breast CancerNCT04711252

Phase 2Q3 2026AZD2936Non-Small-Cell Lung CarcinomaNCT04995523

Phase 2Q3 2026AZD0901Gastric Cancer, Gastroesophageal Junction CancerNCT07143604

Phase 2Q3 2026PlaceboDyslipidaemiaNCT07218900

Phase 3Q3 2026Dato-DXdMetastatic Non-small Cell Lung CancerNCT06417814

Phase 2Q4 2026VolrustomigHepatocellular Carcinoma, Biliary Tract CancerNCT05775159

Phase 3Q4 2026AsthmaNCT06471257

Phase 3Q4 2026CapivasertibBreast CancerNCT06635447

Phase 2Q4 2026AZD0486B-cell Acute Lymphoblastic Leukemia (B-ALL)NCT06137118

Phase 2Q4 2026AZD0754Metastatic Prostate CancerNCT06267729

Phase 2Q4 2026DurvalumabHepatocellular CarcinomaNCT07081633

Phase 2Q4 2026AZD7760Staphylococcus AureusNCT06749457

Phase 2Q4 2026DurvalumabCarcinoma, Non-Small-Cell LungNCT06008093

Primary: Progression-free survival (PFS) in randomized participants (From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months))Enrollment:100/100Sites: 47RANDOMIZED, TREATMENT

Phase 3Q4 2026Cutaneous Lupus ErythematosusNCT06015737

Primary: Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score (At Week 24)Enrollment:306/306Sites: 188RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2026DurvalumabCancerNCT05303532

Phase 3Q1 2027AZD0780Heterozygous Familial HypercholesterolaemiaNCT07000136

Phase 3Q1 2027Placebo (blinded)Systemic Sclerosis, SclerodermaNCT05925803

Phase 3Q1 2027AZD0780Cardiovascular DiseaseNCT07000123

Phase 3Q1 2027Chronic Rhinosinusitis With Nasal PolypsNCT06706817

Phase 2Q1 2027SavolitinibLung CancerNCT05374603

Phase 2Q1 2027AZD0901Gastroesophageal AdenocarcinomaNCT07069712

Phase 2Q1 2027AZD9550Overweight and ObesityNCT06151964

Phase 2Q1 2027AZD4144Sepsis, Acute Kidney InjuryNCT07215702

Phase 3Q1 2027Zibotentan/DapagliflozinChronic Kidney Disease With High ProteinuriaNCT06087835

Phase 3Q1 2027PlaceboDyslipidaemiaNCT06834932

Phase 3Q1 2027OsimertinibCancerNCT05629234

Phase 3Q1 2027AnifrolumabLupus NephritisNCT05138133

Phase 2Q1 2027SurovatamigB-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)NCT06526793

Phase 2Q1 2027Trastuzumab deruxtecanPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerNCT04482309

Phase 2Q1 2027AZD4360Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract CancerNCT06921928

Phase 3Q2 2027OlaparibOvarian Cancer, Breast CancerNCT04421963

Phase 2Q2 2027AZD5148Clostridioides Difficile InfectionNCT07285213

Phase 3Q2 2027CamizestrantBreast Cancer, Early Breast CancerNCT05774951

Phase 3Q2 2027Polymyositis, DermatomyositisNCT06455449

Phase 2Q2 2027Baxdrostat/dapagliflozinChronic Kidney Disease and HypertensionNCT07222917

Phase 2Q2 2027AZD5305Ovarian Cancer, Breast Cancer, Pancreatic CancerNCT04644068

Phase 2Q2 2027VolrustomigMetastatic Colorectal CancerNCT06792695

Phase 2Q2 2027Fluorouracil (5-FU)Gastric CancerNCT04379596

Phase 3Q2 2027balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mgHeart Failure and Impaired Kidney FunctionNCT06307652

Phase 2Q2 2027Acalabrutinib + R-CHOP standard of careMantle-cell LymphomaNCT07029737

Phase 2Q2 2027TozorakimabAsthmaNCT06932263

Phase 3Q2 2027Severe AsthmaNCT06473779

Phase 3Q2 2027Datopotamab DeruxtecanNon-small Cell Lung CancerNCT06564844

Phase 3Q3 2027AcalabrutinibChronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT05057494

Phase 2Q3 2027AZD5863Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal AdenocarcinomaNCT06005493

Phase 3Q3 2027Dato-DXdBreast CancerNCT06103864

Phase 2Q3 2027VolrustomigNon-small Cell Lung CancerNCT06448754

Phase 3Q3 2027OsimertinibNon-Small Cell Lung CancerNCT05120349

Phase 2Q3 2027AZD8421ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)NCT06188520

Phase 3Q3 2027TezepelumabSevere AsthmaNCT07363642

Phase 2Q3 2027AZD9574Advanced Solid MalignanciesNCT05417594

Phase 3Q3 2027BaxdrostatPrimary HyperaldosteronismNCT07007793

Primary: Change from baseline in seated Systolic Blood Pressure (SBP) at Week 8 (At week 8)Enrollment:Target 250Sites: 89RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2027AZD0305Multiple MyelomaNCT06106945

Phase 2Q3 2027AcalabrutinibDiffuse Large B-Cell LymphomaNCT05952024

Primary: Percentage of patients with Grade 3 to 4 treatment emergent adverse events (TEAEs) (Cycle 1 Day 1 (Cycles 1 to 8 is 21 days and Cycles 9 to 28 is 28 days) through End of treatment EoT [30 days of discontinuation] (Up to 3.5 Years))Enrollment:Target 80Sites: 57NA, TREATMENT

Phase 2Q3 2027APOL1-Mediated Kidney DiseaseNCT06824987

Phase 2Q3 2027AZD0120Relapsed/Refractory Multiple MyelomaNCT05850234

Phase 3Q3 2027Dato-DXdBreast CancerNCT05629585

Phase 2Q3 2027AZD8205Breast Cancer, Biliary Tract Carcinoma, Ovarian CancerNCT05123482

Phase 2Q4 2027OsimertinibNon-Small Cell Lung Cancer (NSCLC)NCT05801029

Phase 2Q4 2027Datopotamab deruxtecan (Dato-DXd)Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate CancerNCT05489211

Phase 2Q4 2027AZD8359Metastatic Prostate CancerNCT07529717

Phase 3Q4 2027AsthmaNCT06307665

Primary: Annualized rate of severe asthma exacerbations (AAER) (From Randomization (Day 1) to Week 52 (EOT))Enrollment:Target 440Sites: 135RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2027Puxitatug SamrotecanEndometrial Cancer, Malignant Solid TumourNCT07044336

Phase 3Q4 2027CapivasertibLocally Advanced (Inoperable) or Metastatic Breast CancerNCT04862663

Phase 3Q4 2027Datopotamab deruxtecanNSCLCNCT05687266

Phase 3Q4 2027Eosinophilic AsthmaNCT06750289

Primary: Annualized asthma exacerbation rate (Baseline through Week 48)Enrollment:Target 400Sites: 157RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2027AZD6793Chronic Obstructive Pulmonary Disease (COPD)NCT07082738

Phase 2Q4 2027AZD1163Rheumatoid ArthritisNCT07276581

Primary: Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12 (Week 12)Enrollment:Target 320Sites: 144RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2027VolrustomigLocally Advanced Cervical CancerNCT06079671

Phase 2Q4 2027Selumetinib granule formulationNeurofibromatosis Type 1NCT05309668

Phase 2Q4 2027RilvegostomigGastric CancerNCT05702229

Phase 2Q4 2027CamizestrantAdvanced Breast CancerNCT07427394

Phase 2Q4 2027AZD0292Bronchiectasis With Pseudomonas Aeruginosa ColonizationNCT07088926

Phase 2Q4 2027AZD5851Hepatocellular CarcinomaNCT06084884

Phase 3Q4 2027FulvestrantLocally Advanced or Metastatic Breast CancerNCT06764186

Phase 2Q1 2028AZD5335Ovarian Cancer, Lung Adenocarcinoma, Endometrial CancerNCT05797168

Phase 3Q1 2028SaruparibMetastatic Castration-Sensitive Prostate CancerNCT06120491

Phase 3Q1 2028Dato-DXdBreast CancerNCT07205822

Phase 2Q1 2028AZD5492B-cell MalignanciesNCT06542250

Phase 3Q1 2028BenralizumabEosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)NCT06512883

Phase 3Q1 2028Baxdrostat/dapagliflozinChronic Kidney Disease and HypertensionNCT06268873

Phase 2Q1 2028AZD9793 Intravenous (IV) monotherapyHepatocellular CarcinomaNCT06795022

Phase 2Q1 2028SurovatamigChronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell LymphomaNCT06564038

Phase 2Q1 2028AZD4512B-cell Non-Hodgkin LymphomaNCT07123454

Phase 3Q1 2028BGF MDI 320/14.4/9.6 μgCOPD (Chronic Obstructive Pulmonary Disease)NCT06283966

Phase 3Q1 2028TezepelumabChronic Rhinosinusitis With Nasal PolypsNCT07520162

Phase 3Q1 2028OsimertinibNon-small Cell Lung CancerNCT06350097

Phase 2Q1 2028VolrustomigLocally Advanced Cervical CancerNCT06943833

Phase 3Q2 2028volrustomigLocally Advanced Head and Neck Squamous Cell CarcinomaNCT06129864

Phase 3Q2 2028VolrustomigMetastatic Non-small Cell Lung CancerNCT05984277

Primary: Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1) (Up to approximately 6 years)Enrollment:Target 1,200Sites: 256RANDOMIZED, TREATMENT

Phase 2Q2 2028SurovatamigPrimary Membranous NephropathyNCT07571746

Phase 2Q2 2028B-cell Acute Lymphoblastic Leukemia (B-ALL)NCT07109219

Phase 3Q2 2028TezepelumabAsthmaNCT06023589

Phase 3Q2 2028GemcitabineBiliary Tract CancerNCT06467357

Phase 3Q3 2028DurvalumabNon-Small Cell Lung CancerNCT05211895

Phase 3Q3 2028ElecoglipronWeight ManagementNCT07667803

Phase 3Q3 2028AZD0120Relapsed Refractory Multiple MyelomaNCT07391657

Phase 3Q4 2028AnifrolumabSystemic Lupus ErythematosusNCT05835310

Primary: Part A- Anifrolumab serum concentration (Pre-dose Day 29)Enrollment:Target 100Sites: 97RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2028DurvalumabUrinary Bladder Neoplasms, Immune Checkpoint Inhibitors, MethotrexateNCT06960577

Phase 2Q4 2028AcalabrutinibMantle Cell Lymphoma (MCL)NCT05951959

Phase 3Q4 2028DurvalumabCarcinoma, Non-Small-Cell LungNCT03833154

Phase 3Q4 2028VolrustomigUnresectable Pleural MesotheliomaNCT06097728

Phase 3Q4 2028AZD5335Epithelial Ovarian CancerNCT07218809

Primary: Progression free Survival (PFS) (Up to approximately 5 years)Enrollment:Target 1,100Sites: 125RANDOMIZED, SINGLE, TREATMENT

Phase 3Q4 2028Dato-DXdBreast CancerNCT06112379

Phase 2Q4 2028VolrustomigSub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)NCT06535607

Phase 3Q4 2028Durvalumab + Chemotherapy phaseAdvanced or Recurrent Endometrial CancerNCT06746116

Phase 3Q1 2029RilvegostomigBiliary Tract CancerNCT06109779

Phase 2Q1 2029AZD9750Prostate CancerNCT07336446

Phase 2Q1 2029AZD0516Metastatic Prostate CancerNCT07181161

Phase 3Q1 2029Trastuzumab deruxtecanEndometrial CancerNCT06989112

Phase 3Q1 2029AnifrolumabSystemic Lupus ErythematosusNCT07430306

Phase 3Q1 2029Datopotamab deruxtecan (Dato-DXd)Non-small Cell Lung Cancer (NSCLC)NCT07291037

Primary: Progression-free survival (PFS) (Approximately 2.5 years)Enrollment:Target 400Sites: 204RANDOMIZED, TREATMENT

Phase 3Q1 2029RilvegostomigNon-small Cell Lung CancerNCT06692738

Phase 2Q1 2029AZD3632Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic SyndromesNCT07155226

Phase 2Q1 2029RilvegostomigAdvanced or Metastatic Non-small Cell Lung CancerNCT06996782

Phase 3Q1 2029TezepelumabChronic Obstructive Pulmonary Disease (COPD)NCT06878261

Phase 3Q1 2029TezepelumabChronic Obstructive Pulmonary Disease (COPD)NCT06883305

Phase 3Q1 2029TremelimumabHepatocellular CarcinomaNCT06921785

Primary: To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC (Up to approximately 6 years)Enrollment:Target 1,220Sites: 204RANDOMIZED, SINGLE, TREATMENT

Phase 2Q1 2029AZD6621Prostate CancerNCT07192614

Phase 3Q1 2029Saruparib (AZD5305)Advanced Breast CancerNCT06380751

Phase 2Q2 2029RilvegostomigNon-Small Cell Lung CancerNCT07098338

Phase 3Q2 2029RilvegostomigHER2-positive Gastric Cancer, Gastroesophageal Junction AdenocarcinomaNCT06764875

Phase 2Q2 2029AZD0120Lupus Erythematosus, SystemicNCT06897930

Phase 2Q2 2029AcalabrutinibChronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)NCT07024706

Phase 3Q2 2029RilvegostomigNon-squamous Non-small Cell Lung CancerNCT06627647

Primary: Overall survival (OS) (Up to approximately 5 years)Enrollment:Target 878Sites: 282RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2029AsthmaNCT07525375

Phase 2Q2 2029OsimertinibLung CancerNCT07295821

Phase 3Q2 2029DurvalumabSmall Cell Lung CarcinomaNCT06992609

Phase 2Q2 2029OsimertinibNon-small Cell Lung CancerNCT05546866

Phase 3Q3 2029RilvegostomigBiliary Tract CancerNCT07221253

Phase 3Q3 2029Sonesitatug vedotinGastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal CancerNCT07431281

Phase 2Q3 2029AZD2265 (FPI-2265)Metastatic Prostate CancerNCT07590934

Phase 2Q4 2029AZD6750Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin)NCT07115043

Phase 3Q4 2029AZD0780Cardiovascular DiseaseNCT07000357

Phase 2Q4 2029Osimertinib 80 mg/40 mgStage II-IIIB Non-small Cell Lung CarcinomaNCT05526755

Phase 3Q4 2029Baxdrostat and dapagliflozinHeart FailureNCT06677060

Phase 3Q4 2029Baxdrostat/dapagliflozinChronic Kidney Disease and HypertensionNCT06742723

Phase 3Q4 2029BenralizumabAsthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)NCT07444567

Phase 3Q4 2029Datopotamab DeruxtecanNon-Small Cell Lung CancerNCT06357533

Phase 3Q1 2030RilvegostomigCarcinoma, Non-Small Cell LungNCT06868277

Phase 3Q1 2030Sodium Zirconium Cyclosilicate (SZC) Reduced Dose LevelHyperkalaemiaNCT03813407

Phase 3Q1 2030VolrustomigAdvanced Clear Cell Renal Cell CarcinomaNCT07000149

Phase 3Q1 2030CamizestrantBreast Cancer, Early Breast CancerNCT05952557

Phase 2Q1 2030AZD4956Solid TumoursNCT07446855

Phase 3Q2 2030BenralizumabAsthmaNCT05692180

Phase 2Q2 2030DurvalumabNon-small Cell Lung CancerNCT05061550

Phase 3Q2 2030AZD0486Large B-cell LymphomaNCT07215585

Phase 3Q3 2030Balcinrenone/dapagliflozinRenal Insufficiency, ChronicNCT07624305

Phase 2Q3 2030Systemic Lupus ErythematosusNCT07630714

Phase 2Q2 2031AZD5305Metastatic Prostate CancerNCT05367440

Phase 3Q4 2031SurovatamigUntreated Follicular LymphomaNCT06549595

Phase 3Q4 2032SurovatamigChronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHVNCT07509151

Phase 3Q4 2032AnifrolumabSystemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus ErythematosusNCT07691970

Phase 3Q1 2033SaruparibProstate CancerNCT06952803

ASTRAZENECA PLC

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research